DPP4 in diabetes

D Röhrborn, N Wronkowitz, J Eckel - Frontiers in immunology, 2015 - frontiersin.org
Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed
on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal …

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

RA DeFronzo, JA Davidson… - Diabetes, Obesity and …, 2012 - Wiley Online Library
The maintenance of normal glucose homeostasis requires a complex, highly integrated
interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system …

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

DM Kendall, MC Riddle, J Rosenstock… - Diabetes …, 2005 - Am Diabetes Assoc
OBJECTIVE—This study evaluated the effects of exenatide, a novel incretin mimetic, in
hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with …

Glucose metabolism and regulation: beyond insulin and glucagon

SL Aronoff, K Berkowitz, B Shreiner… - Diabetes spectrum, 2004 - Am Diabetes Assoc
Insulin and glucagon are potent regulators of glucose metabolism. For decades, we have
viewed diabetes from a bi-hormonal perspective of glucose regulation. This perspective is …

[HTML][HTML] A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

L Prasad-Reddy, D Isaacs - Drugs in context, 2015 - ncbi.nlm.nih.gov
The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents
used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight …

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 …

DJ Augeri, JA Robl, DA Betebenner… - Journal of medicinal …, 2005 - ACS Publications
Efforts to further elucidate structure− activity relationships (SAR) within our previously
disclosed series of β-quaternary amino acid linked l-cis-4, 5-methanoprolinenitrile dipeptidyl …

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

RJ Heine, LF Van Gaal, D Johns, MJ Mihm… - Annals of internal …, 2005 - acpjournals.org
Background: Physicians may use either insulin or exenatide injections for patients with type
2 diabetes mellitus who have poor glycemic control despite taking oral blood glucose …

β-cell failure in diabetes and preservation by clinical treatment

BL Wajchenberg - Endocrine reviews, 2007 - academic.oup.com
There is a progressive deterioration in β-cell function and mass in type 2 diabetics. It was
found that islet function was about 50% of normal at the time of diagnosis, and a reduction in …

[HTML][HTML] Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain

DA Butterfield, F Di Domenico, E Barone - Biochimica et Biophysica Acta …, 2014 - Elsevier
Alzheimer disease (AD) is the most common form of dementia among the elderly and is
characterized by progressive loss of memory and cognition. Epidemiological data show that …

Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome

B Kim, EL Feldman - Experimental & molecular medicine, 2015 - nature.com
Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors that includes obesity,
diabetes, and dyslipidemia. Accumulating evidence implies that MetS contributes to the …